前列腺癌主动监测中监测降级的决策:GAP3联盟研究结果
本研究回顾性分析GAP3全球前瞻性主动监测队列中24656例资料完整的患者,旨在建立识别其他原因死亡率与前列腺癌特异性死亡率比值较高亚组的模型。研究发现体重指数(BMI)>25 kg/m²且初次活检阳性针数<11%是区分其他原因死亡与前列腺癌特异性死亡的最佳标准组合。结论认为这组标准可用于前列腺癌主动监测的降级决策。
要点
- BMI>25 kg/m²且初次活检阳性针数<11%可作为主动监测降级候选标准。
- 符合该标准者15年其他原因死亡率与前列腺癌特异性死亡率比值是非符合者的34.2倍。
- 按此标准,37%的队列可考虑降低监测强度。
核心结论
- BMI>25 kg/m²且初次活检阳性针数<11%被确定为前列腺癌主动监测降级的临床标准。
- 符合上述标准亚组的其他原因死亡率与前列腺癌特异性死亡率比值显著高于不符合者。
研究设计与样本
- 基于GAP3联盟全球前瞻性主动监测队列的回顾性分析。
- 纳入24656例结局数据完整的患者。
- 采用非参数竞争风险模型估计病因特异性死亡率。
- 主要目标是建立识别其他原因死亡率与前列腺癌特异性死亡率比值较高亚组的模型。
主要发现
- 15年累积死亡率(考虑删失)为:前列腺癌特异性死亡率1.3%,其他原因死亡率11.5%,未知原因死亡18.7%。
- 符合BMI>25 kg/m²且初次活检阳性针数<11%标准者,15年其他原因死亡率与前列腺癌特异性死亡率比值是非符合者的34.2倍。
- 按该标准,37%的队列符合监测降级条件。
关键数值与推荐
- BMI>25 kg/m²且初次活检阳性针数<11%。
- 符合标准者15年其他原因死亡率与前列腺癌特异性死亡率比值为非符合者的34.2倍。
- 37%的队列符合降级标准。
临床怎么用
- 作者认为BMI>25 kg/m²且初次活检阳性针数<11%的标准有助于医生和患者就前列腺癌主动监测做出决策。
- 作者指出符合该标准的患者可能是降低监测强度的良好候选者。
局限性
- 研究为回顾性分析。
- 缺乏外部验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is no consensus on de-escalation of monitoring during active surveillance (AS) for prostate cancer (PCa). Our objective was to determine clinical criteria that can be used in decisions to reduce the intensity of AS monitoring. METHODS: The global prospective AS cohort from the Global Action Plan prostate cancer AS consortium was retrospectively analyzed. The 24656 patients with complete outcome data were considered. The primary goal was to develop a model identifying a subgroup with a high ratio of other-cause mortality (OCM) to PCa-specific mortality (PCSM). Nonparametric competing-risks models were used to estimate cause-specific mortality. We hypothesized that the subgroup with the highest OCM/PCSM ratio would be good candidates for de-escalation of AS monitoring. KEY FINDINGS AND LIMITATIONS: Cumulative mortality at 15 yr, accounting for censoring, was 1.3% for PCSM, 11.5% for OCM, and 18.7% for death from unknown causes. We identified body mass index (BMI) >25 kg/m2 and <11% positive cores at initial biopsy as an optimal set of criteria for discriminating OCM from PCSM. The 15-yr OCM/PCSM ratio was 34.2 times higher for patients meeting these criteria than for those not meeting the criteria. According to these criteria, 37% of the cohort would be eligible for de-escalation of monitoring. Limitations include the retrospective nature of the study and the lack of external validation. CONCLUSIONS: Our study identified BMI >25 kg/m2 and <11% positive cores at initial biopsy as clinical criteria for de-escalation of AS monitoring in PCa. PATIENT SUMMARY: We investigated factors that could help in deciding on when to reduce the intensity of monitoring for patients on active surveillance for prostate cancer. We found that patients with higher BMI (body mass index) and lower prostate cancer volume may be good candidates for less intensive monitoring. This model could help doctors and patients in making decisions on active surveillance for prostate cancer.
引用
- Tohi Y, Sahrmann JM, Arbet J, et al. De-escalation of Monitoring in Active Surveillance for Prostate Cancer: Results from the GAP3 Consortium. Eur Urol Oncol. 2024. PMID: 39089946. doi:10.1016/j.euo.2024.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。